Form 4: Aligos Therapeutics Executive Modifies Stock Option Holdings Through Exchange Program
SEC Form 4 Filing
Chief Medical Officer Matthew W. McClure participated in Aligos Therapeutics' option exchange program, resulting in the cancellation of existing stock options and the grant of new options with a different exercise price.
Summary
- Matthew W. McClure, Chief Medical Officer of Aligos Therapeutics, participated in the company's option exchange program.
- On February 27, 2024, McClure's existing stock options were canceled.
- In exchange, on February 28, 2024, McClure received new stock options with an exercise price of $0.96 per share.
- The canceled options had exercise prices of $16.18 and $3.06.
- The new options vest over time, contingent on McClure's continued service with the company.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing and does not convey any particularly positive or negative sentiment. It simply reports a change in stock option holdings.
Positives
- The option exchange program may incentivize continued service from the Chief Medical Officer.
- The new options have a lower exercise price, potentially increasing their value to the executive if the stock price rises.
Risks
- The vesting schedules of the new options are contingent on continued service, creating a potential risk if the executive leaves the company before the options fully vest.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's financial performance or future prospects.
Industry Context
Option exchange programs are sometimes used by companies to re-incentivize employees, particularly when the stock price has declined significantly since the original options were granted. This can help retain key personnel and align their interests with those of shareholders.
Stakeholder Impact
- The option exchange program could potentially impact shareholder value depending on the future performance of the company's stock.
- The program is designed to incentivize a key member of the management team.
Key Dates
| Date | Description |
|---|---|
| 01/01/2021 | Date of original grant for 255,626 options with exercise price of $16.18. |
| 03/04/2022 | Date of original grant for 92,000 options with exercise price of $3.06. |
| 02/04/2025 | Date of original grant for 23,000 options with exercise price of $3.06. |
| 02/27/2024 | Cancellation of existing stock options. |
| 02/28/2024 | Grant of new stock options with an exercise price of $0.96 per share. |
| 12/01/2030 | Expiration date for some stock options. |
| 02/04/2032 | Expiration date for some stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.